Chugai Pharmaceutical Co., Ltd. is a research‑based Japanese pharmaceutical company and a majority‑owned member of the Roche Group. Headquartered in Tokyo, it discovers, develops, manufactures, and markets prescription medicines with core strengths in oncology, immunology/inflammation, hematology, and rare diseases. The company is known for its expertise in biologics and antibody engineering.
Chugai’s portfolio includes innovative monoclonal antibodies and small molecules, with notable therapies such as Actemra (tocilizumab), Hemlibra (emicizumab), Alecensa (alectinib), and Enspryng (satralizumab). It collaborates closely with Roche and Genentech on global development and commercialization, and distributes Roche medicines in Japan. Chugai operates R&D and manufacturing facilities primarily in Japan and participates in international clinical programs, supplying biologics to global markets.
None yet. When a new project in the record names Chugai Pharmaceutical as owner, partner or investor, it shows here.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
Wholly owned Korea subsidiary to secure marketing authorizations and build phased in‑house sales for pipeline drugs including sparsentan and NXT007.
Exclusive deal grants development, manufacturing and commercialisation rights for a RAF‑MEK molecular glue; Chugai to receive upfront, royalties and a share of sublicense income.
Emugrobart failed to meet pre-specified weight-loss goals in Phase II GYMINDA; Roche returns rights and the programme will shift toward SMA Phase III while out-licensing is explored.
Interim analysis shows a significant progression‑free survival benefit versus rituximab+lenalidomide in second‑line or later relapsed/refractory follicular lymphoma; safety as expected.
Approval allows FoundationOne CDx to detect BRAF V600 alterations and BRAF fusion genes to guide tovorafenib treatment in glioma and expands companion indications to nine cancer types.
